HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

— FRUZAQLA is the first targeted therapy approved in the U.S. for metastatic colorectal cancer regardless of biomarker status or prior types of therapies in more than a decade — — U.S....

Related Keywords

Japan ,Macau ,Belgium ,Australia ,China ,Panmure ,Victoria ,Hong Kong ,Cairo ,Al Qahirah ,Egypt ,Shanghai ,United States ,Cancer Institute ,Belgian ,American ,Weiguo Su ,Eli Lilly ,Zhou Yi ,Cathy Eng ,Ahcene Djaballah ,Gastroenterol Hepatol ,Ben Atwell Alex Shaw ,Teresa Bitetti ,European Society For Medical Oncology ,International Normalized Ratio ,Nasdaq ,China Limited Nasdaq ,European Union Withdrawal ,Drug Administration ,Vanderbilt University Medical Center ,Japan Pharmaceuticals ,Takeda Pharmaceuticals ,Stock Exchange Of Hong Kong ,Linkedin ,International Agency For Research On Cancer ,Journal Of The American Medical Association ,Devices Agency ,National Cancer Institute ,Exchange Commission ,European Medicines Agency ,Priority Review ,Prescription Drug Users Fee Act ,Chief Executive Officer ,Chief Scientific Officer ,Global Oncology Business Unit ,American Medical ,Vanderbilt University Medical ,Medical Devices Agency ,Plantar Erythrodysesthesia ,Reversible Encephalopathy Syndrome ,Sunset Yellow ,Prescribing Information ,International Agency ,European Society ,Medical Oncology ,Securities Litigation Reform Act ,Stock Exchange ,European Union ,Alex Shaw ,Freddy Crossley ,Daphne Zhang ,Cancer Res ,Cancer Biol ,Soc Clin Oncol Educ ,Cancer Statistics ,Mortality Worldwide ,Rev Gastroenterol Hepatol ,Clinical Cancer Res ,Colorectal Cancer ,Winding Road From Negative Predictive Factor ,Positive Actionable ,Markets ,